Dietary Management - The Cornerstone Strategy
- Goal: Maintain euglycemia & prevent hypoglycemia.
- Uncooked Cornstarch (UCCS): Cornerstone for GSD I, III, IV, VI, IX.
- Provides slow, steady glucose release.
- Dose: 1.6-2.5 g/kg every 4-6 hours.
- Must be uncooked and mixed in cool water.
- Dietary Restrictions (GSD I):
- Strict avoidance of fructose, sucrose, galactose, & lactose.
- Prevents worsening of lactic acidosis & hyperlipidemia.
- Specific Modifications:
- GSD III: High-protein diet supports gluconeogenesis.
- GSD V (McArdle): Pre-exercise sucrose (~30g) can improve exercise tolerance.
⭐ Uncooked cornstarch (UCCS) therapy revolutionized GSD I management, dramatically improving survival and reducing reliance on continuous nocturnal feedings.
Pharmacotherapy & ERT - The Medical Arsenal
-
GSD I (von Gierke's Disease):
- Allopurinol: Manages hyperuricemia to prevent gout and nephropathy.
- Citrate supplements: Alkalinize urine, reducing risk of uric acid stones.
- Lipid-lowering agents: Statins or fibrates for severe hypertriglyceridemia.
- G-CSF (Filgrastim): For neutropenia and recurrent infections in GSD Ib.
-
GSD II (Pompe Disease):
- Enzyme Replacement Therapy (ERT): The cornerstone of treatment.
- Alglucosidase alfa (Myozyme®, Lumizyme®): A recombinant human acid α-glucosidase (GAA) administered via regular IV infusions.
-
GSD V (McArdle's Disease):
- Pre-exercise sucrose/glucose: Provides an alternative, readily available fuel source.
- Vitamin B6 (Pyridoxine): Cofactor for muscle glycogen phosphorylase; may offer some benefit.
⭐ In Pompe disease, ERT dramatically improves hypertrophic cardiomyopathy and survival in infants, but its efficacy on skeletal muscle function in late-onset disease is more variable.

Monitoring & Complications - The Long-Term View
- Routine Surveillance: Lifelong, multidisciplinary follow-up is key.
- Growth: Serial height/weight, bone age.
- Biochemical: Glucose, lactate, lipid panel, uric acid.
- Liver: Annual LFTs & ultrasound (from age 10 for GSD I).
- Renal: Annual urinalysis (microalbuminuria), creatinine, electrolytes.
- Cardiac: ECG/ECHO for GSD III, IV.
- Long-Term Complications:
- Hepatic: Hepatic adenomas (GSD I) → risk of hemorrhage or malignant transformation to HCC.
- Renal: Nephromegaly, progressive renal insufficiency, Fanconi syndrome.
- Bone: Osteopenia/osteoporosis.
- Hematologic: Anemia, platelet dysfunction.

⭐ In GSD I, hepatic adenomas can regress with strict dietary therapy, but the risk of malignant transformation into hepatocellular carcinoma (HCC) remains a lifelong concern.
High‑Yield Points - ⚡ Biggest Takeaways
- The primary goal is to maintain euglycemia and prevent hypoglycemia.
- Management relies on dietary therapy, including frequent small meals and continuous nocturnal feeds.
- Uncooked cornstarch is a cornerstone, providing slow-release glucose, especially overnight.
- In GSD I (von Gierke), it's crucial to avoid fructose and galactose.
- Allopurinol is used to treat the hyperuricemia associated with GSD I.
- For GSD V (McArdle), management includes sucrose before exercise.
- GSD II (Pompe) is uniquely treated with enzyme replacement therapy (ERT).
Continue reading on Oncourse
Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.
CONTINUE READING — FREEor get the app